Enzo Biochem (ENZ) 10-Q2020 Q3 Quarterly report

Filed: 9 Jun 20, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Additionally, affiliated, aforementioned, agency, Aid, antibody, Article, assistance, augmenting, Authorization, back, began, broader, cancelation, cancellation, cancelled, chain, CHF, CMS, committed, comply, context, coordinated, Corona, covenant, creditor, curtailing, deemed, distancing, documentation, documented, driven, duration, eased, economy, eligibility, eligible, emergency, employee, en, EUA, evolving, exacerbate, expenditure, explained, failure, FDA, forecasted, forgiven, half, hamper, healthy, HHS, highly, Human, inter, invoiced, iv, knowledge, Krise, LDT, lessen, light, long, lost, magnitude, media, mentioned, moderated, national, noncompliance, outbreak, pandemic, passed, Paycheck, payroll, penalty, persist, personnel, power, PPP, prepaid, prolonged, publicly, purported, purpose, put, ratio, recessionary, recoverable, recovery, refinance, regulatory, remote, repaid, repay, replace, reprieve, rest, restore, safe, salary, satisfy, SBA, scope, sector, sequestration, serological, short, show, small, social, specimen, speed, spent, spread, strain, sum, supply, suspended, Suspending, suspension, Switzerland, target, technical, temporarily, theinter, thereunder, Trademark, tranche, travel, twenty, uncollateralized, unconditional, undetermined, unprecedented, unrecouped, usage, verified, voluntarily, waiver, week, withheld, workforce, worse

Removed: argument, final, gain, heard, international, monitored, procedural, PTAB, regularly, remand, reverse, twointer

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ENZ transcripts

ENZ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
TITLE 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-Q for the period ended April 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Elazar Rabbani, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: June 9, 2020

	By:	/s/ Elazar Rabbani, Ph.D.
		Elazar Rabbani, Ph.D.
		Chairman of the Board, Chief Executive Officer and Director